ArticleFrontiers in immunology2026
Identification of key amino acids defining conformational neutralizing epitopes of coxsackievirus A5 using monoclonal antibody escape mutants.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coxsackievirus A5 (CVA5) is an emerging pathogen associated with severe hand, foot, and mouth disease. Protective antibodies are critical for protection from CVA5 infection, yet the antigenic determinants of CVA5 remain poorly defined. In this study, we aimed to map the conformational neutralizing epitopes of CVA5 using monoclonal antibodies (mAbs) and escape mutant analysis. Methods: Two IgG, one IgA, and five IgM neutralizing mAbs were purified and characterized for binding affinity and neutralization potency. Antibody pressure selection was applied to generate immune escape mutants, and comparative sequence analysis with wild-type virus identified potential critical residues. Reverse genetics was used to confirm key sites pivotal for mAb recognition. Structural mapping was performed to localize these sites on the viral capsid. Results: Ten key sites (K1103, V1215, N1282, F1288, T1291, K2076, E2160, T3059, D3060, E3139) were confirmed to be pivotal for mAb recognition. Structural mapping revealed distinct localization of these sites on the viral capsid: V1215, N1282, F1288, T1291, K2076, E2160, T3059, D3060 at the southern rim; K1103 at the canyon's northern rim; and E3139 near the two-fold axis. Conclusion: This study provides the first evidence of multiple conformational neutralizing epitopes on CVA5. These findings define the antigenic basis of CVA5 neutralization and offer a structural framework for vaccine and antibody-based therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.